Valuation: Valneva SE

Market Cap 434M 496M 400M 370M 702M 47.32B 714M 4.79B 1.88B 23.24B 1.86B 1.82B 80.5B P/E 2026 *
-6.23x
P/E 2027 * 6.02x
Enterprise Value 562M 642M 518M 479M 910M 61.29B 925M 6.2B 2.43B 30.1B 2.41B 2.36B 104B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 1.68x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -
1 day-0.74%
1 week-2.87%
Current month+0.67%
1 month+1.07%
3 months-15.14%
6 months-46.16%
Current year-38.95%
1 week 2.22
Extreme 2.222
2.36
1 month 2.16
Extreme 2.156
2.37
Current year 2.14
Extreme 2.135
5.15
1 year 2.14
Extreme 2.135
5.42
3 years 1.73
Extreme 1.726
7.24
5 years 1.73
Extreme 1.726
29.7
10 years 1.73
Extreme 1.726
29.7
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 29/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 20/12/2023
Director/Board Member 75 07/03/2013
Chairman 65 20/12/2023
Date Insider Type Main position Quantity % Market Cap.
01-27Sell

Chief Technology Officer

11,800 0.0069%
01-26Sell

Chief Financial Officer

11,800 0.0069%
01-19Sell

Chief Operating Officer

6,206 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%-2.87%-10.98%-65.08% 496M
+1.15%+2.47%+3.34%+11.31% 50.44B
+0.72%+1.00%+396.18%+624.25% 40.63B
+2.54%+0.93%+28.98%-3.62% 34.88B
+0.31%+1.74%+18.44%+59.76% 33.67B
-2.09%-1.98%+3.21%+33.56% 26.29B
-0.63%+0.34% - - 17.11B
+0.66%-3.96%+66.85%+127.36% 15.29B
-23.90%-21.43%+50.06%+53.83% 10.62B
+1.19%+0.37%+14.85%+22.27% 13.74B
Average -2.07%-2.25%+63.44%+95.96% 24.32B
Weighted average by Cap. -0.43%-0.60%+87.30%+139.33%

Financials

2026 *2027 *
Net sales 152M 174M 140M 130M 246M 16.57B 250M 1.68B 657M 8.13B 652M 637M 28.18B 294M 336M 271M 251M 476M 32.08B 484M 3.25B 1.27B 15.75B 1.26B 1.23B 54.57B
Net income -66.01M -75.46M -60.88M -56.33M -107M -7.2B -109M -729M -286M -3.54B -283M -277M -12.25B 70.5M 80.59M 65.01M 60.15M 114M 7.69B 116M 779M 305M 3.78B 303M 296M 13.09B
Net Debt 128M 146M 118M 109M 207M 13.97B 211M 1.41B 554M 6.86B 549M 537M 23.76B 60.02M 68.61M 55.35M 51.21M 97.2M 6.55B 98.82M 663M 260M 3.22B 258M 252M 11.14B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
674
Date Price Change Volume
10/07/26 2.278 -0.39% 40,290
09/07/26 €2.287 +0.18% 144,492
08/07/26 €2.283 -0.09% 340,101
07/07/26 €2.285 -1.08% 498,958
06/07/26 €2.310 -1.16% 390,753
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.287EUR
Average target price
5.233EUR
Spread / Average Target
+128.83%

Quarterly revenue - Rate of surprise